Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluation of safety, effectiveness and tolerability of the Aventix Medical Device used for the treatment of chronic rhinitis
The NOVOCLEARâ„¢ Device is a radiofrequency-based hand-held device intended to treat chronic rhinitis by delivering pulsed field energy to soft tissues in the nasal airway, including the posterior nasal nerve distribution. The NOVOCLEARâ„¢ Device is used with the AVENTIXâ„¢ PFX System. The AVENTIXâ„¢ PFX System is a radiofrequency-based electrosurgical system designed to deliver non-thermal pulsed field energy to the targeted tissue.
This is a non-significant risk, prospective, multi-center, single arm study to evaluate the safety, effectiveness and tolerability of the NOVOCLEARâ„¢ Device used with the AVENTIXâ„¢ PFX System.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NOVOCLEARâ„¢ Device Treatment Group | Experimental | Subjects treated with pulsed field energy applied to soft tissues in the nasal airway, including the posterior nasal nerve distribution. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NOVOCLEARâ„¢ Device | Device | Pulsed field energy applied to soft tissues in the nasal airway, including the posterior nasal nerve distribution. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean change in Reflective Total Nasal Symptom Score (rTNSS) at 90 days compared to baseline. | The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. Total scores range from 0 to 12. A higher score indicates increased symptom severity. | 90 days |
| Proportion of subjects with device and/or procedure-related serious adverse events through 90 days | Characterization of the type and frequency of study device and/or study procedure-related adverse events reported during or following the study procedure through 90 days follow-up. | 90 days |
| Measure | Description | Time Frame |
|---|---|---|
| Mean change in rTNSS at 7 days compared to baseline | The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. Total scores range from 0 to 12. A higher score indicates increased symptom severity. | 7 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| ClinicalAdmin | Contact | (510) 912-2589 | clinical@aventixmed.com |
| Name | Affiliation | Role |
|---|---|---|
| Raymond Weiss, MD | Bay Area ENT | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Colorado ENT and Allergy | Recruiting | Colorado Springs | Colorado | 80923 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012220 | Rhinitis |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Mean change in rTNSS at 14 days compared to baseline | The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. Total scores range from 0 to 12. A higher score indicates increased symptom severity. | 14 days |
| Mean change in rTNSS at 30 days compared to baseline | The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. Total scores range from 0 to 12. A higher score indicates increased symptom severity. | 30 days |
| Mean change in rTNSS at 6 months compared to baseline | The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. Total scores range from 0 to 12. A higher score indicates increased symptom severity. | 6 months |
| Mean change in rTNSS at 1 year compared to baseline | The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. Total scores range from 0 to 12. A higher score indicates increased symptom severity. | 1 year |
| Mean procedure tolerability using a Visual Analogue Scale (VAS) at post-procedure | Immediately after the study procedure, subjects will be asked to rate the pain they experienced in their nasal cavity(ies) during the procedure using a 100 mm visual analogue scale with 0 mm representing no pain and 100 mm representing worst pain imaginable. | Post-procedure |
| Subject satisfaction at 90 days | Subjects will be asked two questions regarding their satisfaction with the study procedure. The first question asks; How satisfied with your procedure are you?; with the following five response options: very satisfied, satisfied, neutral, unsatisfied, or very unsatisfied. The second question asks; How likely are you to refer a friend for this procedure?; with the following five response options: very likely, likely, neutral, unlikely, or very unlikely. | 90 days |
| Bay Area ENT | Recruiting | Ocean Springs | Mississippi | 39564 | United States |
|
| Atkins Expert Sinus Care | Recruiting | San Antonio | Texas | 78256 | United States |
|
| D010038 |
| Otorhinolaryngologic Diseases |